For: | Saitou Y, Shiraki K, Yamanaka Y, Yamaguchi Y, Kawakita T, Yamamoto N, Sugimoto K, Murata K, Nakano T. Noninvasive estimation of liver fibrosis and response to interferon therapy by a serum fibrogenesis marker, YKL-40, in patients with HCV-associated liver disease. World J Gastroenterol 2005; 11(4): 476-481 [PMID: 15641129 DOI: 10.3748/wjg.v11.i4.476] |
---|---|
URL: | https://www.wjgnet.com/1007-9327/full/v11/i4/476.htm |
Number | Citing Articles |
1 |
Ki Tae Suk, Dae Yong Kim, Kyoung Min Sohn, Dong Joon Kim. . Advances in Clinical Chemistry 2013; 62: 33 doi: 10.1016/B978-0-12-800096-0.00002-0
|
2 |
|
3 |
Krishna Sumanth Nallagangula, Shashidhar Kurpad Nagaraj, Lakshmaiah Venkataswamy, Muninarayana Chandrappa. Liver Fibrosis: A Compilation on the Biomarkers Status and Their Significance During Disease Progression. Future Science OA 2018; 4(1) doi: 10.4155/fsoa-2017-0083
|
4 |
Hind I. Fallatah. Noninvasive Biomarkers of Liver Fibrosis: An Overview. Advances in Hepatology 2014; 2014: 1 doi: 10.1155/2014/357287
|
5 |
Xiaoting Huang, Jialing Zhuang, Yongqiang Yang, Jiaxin Jian, Wen Ai, Chunyong Liu, Wenzhi Tang, Changyu Jiang, Yongshen He, Lesheng Huang, Se Peng, Jin Shui Pan. Diagnostic Value of Serum Chitinase-3-Like Protein 1 for Liver Fibrosis: A Meta-analysis. BioMed Research International 2022; 2022: 1 doi: 10.1155/2022/3227957
|
6 |
Linlin Yan, Yongqiong Deng, Jiyuan Zhou, Hong Zhao, Guiqiang Wang. Serum YKL-40 as a biomarker for liver fibrosis in chronic hepatitis B patients with normal and mildly elevated ALT. Infection 2018; 46(3): 385 doi: 10.1007/s15010-018-1136-2
|
7 |
Maria Musumeci, Vincenzo Caruso, Emilia Medulla, Venerando Torrisi, Roberta Migale, Silvia Angeletti, Salvatore Musumeci. Serum YKL-40 Levels and Chitotriosidase Activity in Patients with Beta-Thalassemia Major. Disease Markers 2014; 2014: 1 doi: 10.1155/2014/965971
|
8 |
Chun Geun Lee, Carla A. Da Silva, Charles S. Dela Cruz, Farida Ahangari, Bing Ma, Min-Jong Kang, Chuan-Hua He, Seyedtaghi Takyar, Jack A. Elias. Role of Chitin and Chitinase/Chitinase-Like Proteins in Inflammation, Tissue Remodeling, and Injury. Annual Review of Physiology 2011; 73(1): 479 doi: 10.1146/annurev-physiol-012110-142250
|
9 |
Stephanie J. Bissel, Julia Kofler, Julia Nyaundi, Michael Murphey-Corb, Stephen R. Wisniewski, Clayton A. Wiley. Cerebrospinal Fluid Biomarkers of Simian Immunodeficiency Virus Encephalitis. Journal of Neuroimmune Pharmacology 2016; 11(2): 332 doi: 10.1007/s11481-016-9666-9
|
10 |
Mohamed M. Zeweil, Kadry M. Sadek, Mohamed F. Elsadek, Sahar F. Mahmoud, Badreldin M. Ahmed, Asmaa F. Khafaga. Sidr honey abrogates the oxidative stress and downregulates the hyaluronic acid concentration and gene expression of TGF‐β1 and COL1a1 in rat model of thioacetamide‐induced hepatic fibrosis. Animal Science Journal 2020; 91(1) doi: 10.1111/asj.13434
|
11 |
Chun Geun Lee, Charles S. Dela Cruz, Bing Ma, Farida Ahangari, Yang Zhou, Ruth Halaban, Mario Sznol, Jack A. Elias. Chitinase-like Proteins in Lung Injury, Repair, and Metastasis. Proceedings of the American Thoracic Society 2012; 9(2): 57 doi: 10.1513/pats.201112-056MS
|
12 |
Ajay K. Muddu, Indra Neil Guha, Ahmed M. Elsharkawy, Derek A. Mann. Resolving fibrosis in the diseased liver: Translating the scientific promise to the clinic. The International Journal of Biochemistry & Cell Biology 2007; 39(4): 695 doi: 10.1016/j.biocel.2006.10.006
|
13 |
Vera Regina Rodrigues Camacho, Themis Reverbel da Silveira, Jarbas Rodrigues de Oliveira, Sérgio Gabriel Silva de Barros, Carlos Thadeu Schmidt Cerski. Relationship between serum concetrations of type III procollagen, hyluronic acid and histopathological findings in the liver of HCV-positive blood donors. Arquivos de Gastroenterologia 2007; 44(2): 118 doi: 10.1590/S0004-28032007000200006
|
14 |
Paul J. Thuluvath, Karen L. Krok. Noninvasive Markers of Fibrosis for Longitudinal Assessment of Fibrosis in Chronic Liver Disease: Are They Ready for Prime Time?. The American Journal of Gastroenterology 2005; 100(9): 1981 doi: 10.1111/j.1572-0241.2005.00284.x
|
15 |
Chen-Hua Liu, Jia-Horng Kao. Noninvasive Diagnosis of Hepatic Fibrosis in Hemodialysis Patients with Hepatitis C Virus Infection. Diagnostics 2022; 12(10): 2282 doi: 10.3390/diagnostics12102282
|
16 |
Waqar Ahmad, Bushra Ijaz, Sana Gull, Sultan Asad, Saba Khaliq, Shah Jahan, Muhammad T Sarwar, Humera Kausar, Aleena Sumrin, Imran Shahid, Sajida Hassan. A brief review on molecular, genetic and imaging techniques for HCV fibrosis evaluation. Virology Journal 2011; 8(1) doi: 10.1186/1743-422X-8-53
|
17 |
Pamela Valva, Paola Casciato, Juan M. Diaz Carrasco, Adrian Gadano, Omar Galdame, María Cristina Galoppo, Eduardo Mullen, Elena De Matteo, María Victoria Preciado, Ravi Jhaveri. The Role of Serum Biomarkers in Predicting Fibrosis Progression in Pediatric and Adult Hepatitis C Virus Chronic Infection. PLoS ONE 2011; 6(8): e23218 doi: 10.1371/journal.pone.0023218
|
18 |
Seth D. Crockett, Tonya Kaltenbach, Emmet B. Keeffe. Do We Still Need a Liver Biopsy? Are the Serum Fibrosis Tests Ready for Prime Time?. Clinics in Liver Disease 2006; 10(3): 513 doi: 10.1016/j.cld.2006.08.009
|
19 |
Zhiyang Chen, Yichen Ma, Jingyao Cai, Mei Sun, Ling Zeng, Fengxi Wu, Yiru Zhang, Min Hu. Serum biomarkers for liver fibrosis. Clinica Chimica Acta 2022; 537: 16 doi: 10.1016/j.cca.2022.09.022
|
20 |
Julia Kzhyshkowska, Alexei Gratchev, Sergij Goerdt. Human Chitinases and Chitinase-Like Proteins as Indicators for Inflammation and Cancer. Biomarker Insights 2007; 2: 117727190700200 doi: 10.1177/117727190700200023
|
21 |
Ángel Palacios Pérez, Javier Salmerón Escobar. Papel de la biopsia hepática en el diagnóstico y el control de la hepatitis C crónica. Gastroenterología y Hepatología 2007; 30(7): 402 doi: 10.1157/13108806
|
22 |
Marie-Luise Berres, Sven Papen, Katrin Pauels, Petra Schmitz, Mirko Moreno Zaldivar, Claus Hellerbrand, Tobias Mueller, Thomas Berg, Ralf Weiskirchen, Christian Trautwein, Hermann E. Wasmuth. A functional variation in CHI3L1 is associated with severity of liver fibrosis and YKL-40 serum levels in chronic hepatitis C infection. Journal of Hepatology 2009; 50(2): 370 doi: 10.1016/j.jhep.2008.09.016
|
23 |
Ana Carolina Cardoso, Claudio Figueiredo-Mendes, Cristiane A. Villela-Nogueira, Patrick Marcellin. Staging Fibrosis in Chronic Viral Hepatitis. Viruses 2022; 14(4): 660 doi: 10.3390/v14040660
|
24 |
Sheng-Nan Lu, Jing-Houng Wang, Kwong-Ming Kee, Po-Lin Tseng. Liver Cancer. 2009; : 137 doi: 10.1007/978-1-4020-9804-8_10
|
25 |
Thomas Pembroke, Giada Sebastiani. Diagnostic Methods for Cirrhosis and Portal Hypertension. 2018; : 63 doi: 10.1007/978-3-319-72628-1_5
|
26 |
Julia Maroto-García, Ana Moreno-Álvarez, María P. Sanz de Pedro, Antonio Buño-Soto, Álvaro González. Biomarcadores séricos para la evaluación de la fibrosis hepática. Advances in Laboratory Medicine / Avances en Medicina de Laboratorio 2024; 5(2): 131 doi: 10.1515/almed-2023-0172
|
27 |
Joy K. Saha, Jinqi Xia, George E. Sandusky, Yun-Fei Chen, Bruce Gerlitz, Brian Grinnell, Joseph A. Jakubowski. Study of plasma protein C and inflammatory pathways: Biomarkers for dimethylnitrosamine-induced liver fibrosis in rats. European Journal of Pharmacology 2007; 575(1-3): 158 doi: 10.1016/j.ejphar.2007.07.052
|
28 |
Fazilet Duygu, Suda Tekin Koruk, Hasan Karsen, Nurten Aksoy, Abdullah Taskin, Melek Hamidanoglu. Prolidase and Oxidative Stress in Chronic Hepatitis C. Journal of Clinical Laboratory Analysis 2012; 26(4): 232 doi: 10.1002/jcla.21510
|
29 |
Robert J. Fontana, Herbert L. Bonkovsky, Deepa Naishadham, Jules L. Dienstag, Richard K. Sterling, Anna S.F. Lok, Grace L. Su. Serum Fibrosis Marker Levels Decrease After Successful Antiviral Treatment in Chronic Hepatitis C Patients With Advanced Fibrosis. Clinical Gastroenterology and Hepatology 2009; 7(2): 219 doi: 10.1016/j.cgh.2008.10.034
|
30 |
Frank Czul, Kalyan R. Bhamidimarri. Noninvasive Markers to Assess Liver Fibrosis. Journal of Clinical Gastroenterology 2016; 50(6): 445 doi: 10.1097/MCG.0000000000000534
|
31 |
Wen-Jing Lu, Nishant Saxena, John M. Luk, Sunil C. Kaul, Renu Wadhwa. Circulating mortalin autoantibody—a new serological marker of liver cirrhosis. Cell Stress and Chaperones 2015; 20(4): 715 doi: 10.1007/s12192-015-0592-1
|
32 |
Reshmi Chatterjee, Abhisek Mitra. An overview of effective therapies and recent advances in biomarkers for chronic liver diseases and associated liver cancer. International Immunopharmacology 2015; 24(2): 335 doi: 10.1016/j.intimp.2014.12.024
|
33 |
Xingwei Hu, Wenhan Liu, Jianhua Liu, Bojian Wang, Xiaosong Qin. Research advances in serum chitinase-3-like protein 1 in liver fibrosis. Frontiers in Medicine 2024; 11 doi: 10.3389/fmed.2024.1372434
|
34 |
Pan Jo Kim, Dae Gy Hong, Ji Young Park, Young Lae Cho, Il Soo Park, Yoon Soon Lee. Immunohistochemical expression of YKL-40 in peritoneal endometriosis. Gynecological Endocrinology 2010; 26(1): 58 doi: 10.3109/09513590903184068
|
35 |
L. L. Schiavon, J. L. Narciso‐Schiavon, R. J. Carvalho Filho, J. P. Sampaio, J. O. Medina‐Pestana, V. P. Lanzoni, A. E. B. Silva, M. L. G. Ferraz. Serum levels of YKL‐40 and hyaluronic acid as noninvasive markers of liver fibrosis in haemodialysis patients with chronic hepatitis C virus infection. Journal of Viral Hepatitis 2008; 15(9): 666 doi: 10.1111/j.1365-2893.2008.00992.x
|
36 |
Adília Hormigo, Bin Gu, Sasan Karimi, Elyn Riedel, Katherine S. Panageas, Mark A. Edgar, Meena K. Tanwar, Jasti S. Rao, Martin Fleisher, Lisa M. DeAngelis, Eric C. Holland. YKL-40 and Matrix Metalloproteinase-9 as Potential Serum Biomarkers for Patients with High-Grade Gliomas. Clinical Cancer Research 2006; 12(19): 5698 doi: 10.1158/1078-0432.CCR-06-0181
|
37 |
Ivan Gentile, Nicola Coppola, Giuseppe Pasquale, Raffaele Liuzzi, Maria D’Armiento, Maria Emma Di Lorenzo, Nicolina Capoluongo, Antonio Riccardo Buonomo, Evangelista Sagnelli, Filomena Morisco, Nicola Caporaso, Guglielmo Borgia. A Simple Noninvasive Score Based on Routine Parameters can Predict Liver Cirrhosis in Patients With Chronic Hepatitis C. Hepatitis Monthly 2013; 13(5) doi: 10.5812/hepatmon.8352
|
38 |
Mehmet Horoz, Mehmet Aslan, Fusun F. Bolukbas, Cengiz Bolukbas, Yasar Nazligul, Hakim Celik, Nurten Aksoy. Serum prolidase enzyme activity and its relation to histopathological findings in patients with non‐alcoholic steatohepatitis. Journal of Clinical Laboratory Analysis 2010; 24(3): 207 doi: 10.1002/jcla.20334
|
39 |
Marzena Mazur, Anna Zielińska, Marcin M. Grzybowski, Jacek Olczak, Jakub Fichna. Chitinases and Chitinase-Like Proteins as Therapeutic Targets in Inflammatory Diseases, with a Special Focus on Inflammatory Bowel Diseases. International Journal of Molecular Sciences 2021; 22(13): 6966 doi: 10.3390/ijms22136966
|
40 |
Camilla Nøjgaard, Julia S. Johansen, Peter Bjerregaard, Stig E. Bojesen, Ulrik Becker. Plasma YKL-40 in Inuit and Danes. Alcohol and Alcoholism 2015; 50(1): 11 doi: 10.1093/alcalc/agu072
|
41 |
Robert J. Fontana, Zachary D. Goodman, Jules L. Dienstag, Herbert L. Bonkovsky, Deepa Naishadham, Richard K. Sterling, Grace L. Su, Mita Ghosh, Elizabeth C. Wright. Relationship of serum fibrosis markers with liver fibrosis stage and collagen content in patients with advanced chronic hepatitis C. Hepatology 2008; 47(3): 789 doi: 10.1002/hep.22099
|
42 |
Minal J Sangwaiya, David IN Sherman, David J Lomas, Philip J Shorvon. Latest developments in the imaging of fibrotic liver disease. Acta Radiologica 2014; 55(7): 802 doi: 10.1177/0284185113510159
|
43 |
Julia Kzhyshkowska, Srinivas Mamidi, Alexei Gratchev, Elisabeth Kremmer, Christina Schmuttermaier, Liis Krusell, Georg Haus, Jochen Utikal, Kai Schledzewski, Joachim Scholtze, Sergij Goerdt. Novel stabilin-1 interacting chitinase-like protein (SI-CLP) is up-regulated in alternatively activated macrophages and secreted via lysosomal pathway. Blood 2006; 107(8): 3221 doi: 10.1182/blood-2005-07-2843
|
44 |
A. D. Kjaergaard, J. S. Johansen, S. E. Bojesen, B. G. Nordestgaard. Role of inflammatory marker YKL-40 in the diagnosis, prognosis and cause of cardiovascular and liver diseases. Critical Reviews in Clinical Laboratory Sciences 2016; 53(6): 396 doi: 10.1080/10408363.2016.1190683
|
45 |
Mengqi Shi, Qianyun Ge, Xinrong Wang, Wenbin Diao, Ben Yang, Sipeng Sun, Guohui Wang, Tian Liu, Andrew Man-Lok Chan, Zhiqin Gao, Yi Wang, Yubing Wang. Functional analysis of the short splicing variant encoded by CHI3L1/YKL-40 in glioblastoma. Frontiers in Oncology 2022; 12 doi: 10.3389/fonc.2022.910728
|
46 |
Axel M. Gressner, Mohamed Rizk, Chunfang Gao, Olav A. Gressner. Potential novel biomarkers for monitoring the fibrogenic process in liver. Arab Journal of Gastroenterology 2010; 10(4): S12 doi: 10.1016/j.ajg.2009.12.009
|
47 |
Abdelfattah Hanno, Ali M. EL-Kady, Essam Bedewy, Reham A. Abo Elwafa, Mohammed S. Ahmed. Diagnostic validity of serum YKL-40 as a non-invasive diagnostic marker of oesophageal varices in cirrhotic hepatitis C virus patients. Egyptian Liver Journal 2022; 12(1) doi: 10.1186/s43066-022-00208-w
|
48 |
Feng Xia, Eric C. H. Lai, Wan-Yee Lau, Kuansheng Ma, Xiaowu Li, Ping Bie, Cheng Qian. High Serum Hyaluronic Acid and HBV Viral Load are Main Prognostic Factors of Local Recurrence after Complete Radiofrequency Ablation of Hepatitis B-Related Small Hepatocellular Carcinoma. Annals of Surgical Oncology 2012; 19(4): 1284 doi: 10.1245/s10434-011-2042-3
|
49 |
Laurent Castera. Transient elastography and other noninvasive tests to assess hepatic fibrosis in patients with viral hepatitis. Journal of Viral Hepatitis 2009; 16(5): 300 doi: 10.1111/j.1365-2893.2009.01087.x
|
50 |
MM Sira, HA El-Araby, EM Ghoneim, HA Konsowa, EH El-Mwafy. Serum YKL-40 (Chitinase-3-Like Protein 1) Compared to APRI and FIB-4 in Predicting Liver Fibrosis in Children with Chronic Hepatitis C. Archives of Hepatitis Research 2016; 2(1): 015 doi: 10.17352/ahr.000006
|
51 |
Giada Sebastiani, Konstantinos Gkouvatsos, Kostas Pantopoulos. Chronic hepatitis C and liver fibrosis. World Journal of Gastroenterology 2014; 20(32): 11033-11053 doi: 10.3748/wjg.v20.i32.11033
|
52 |
Jung Woo Shin, Neung Hwa Park. Clinical Application of Non-invasive Diagnostic Tests for Liver Fibrosis. The Korean Journal of Gastroenterology 2016; 68(1): 4 doi: 10.4166/kjg.2016.68.1.4
|
53 |
Dennis Eurich, Ulf P Neumann, Sabine Boas‐Knoop, Ruth Neuhaus, Anja Kiessling, Ali Yahyazadeh, Christian Trautwein, Hermann Wasmuth, Gero Puhl, Peter Neuhaus, Marcus Bahra. YKL‐40‐gene polymorphism affects acute cellular rejection and fibrosis progression after transplantation for hepatitis C virus‐induced liver disease. Journal of Gastroenterology and Hepatology 2013; 28(1): 153 doi: 10.1111/j.1440-1746.2012.07270.x
|
54 |
Qian Kang, Jianhong Chen, Hao Luo, Ning Tan, Hui Gao, Xiaxia Zhang, Min Yu, Dan Liu, Hongli Xi, Yaoyu An, Yifan Han, Ran Cheng, Xiaoyuan Xu. Decrease in Chitinase 3-Like Protein 1 Levels Reflects Improvement in Liver Fibrosis after HCV Eradication. Disease Markers 2020; 2020: 1 doi: 10.1155/2020/8539804
|
55 |
Wilma Debernardi-Venon, Silvia Martini, Fiorella Biasi, Barbara Vizio, Angela Termine, Giuseppe Poli, Franco Brunello, Carlo Alessandria, Renato Bonardi, Giorgio Saracco, Mario Rizzetto, Alfredo Marzano. AT1 receptor antagonist Candesartan in selected cirrhotic patients: Effect on portal pressure and liver fibrosis markers. Journal of Hepatology 2007; 46(6): 1026 doi: 10.1016/j.jhep.2007.01.017
|
56 |
Paul J Thuluvath, Karen L Krok. Noninvasive Markers of Fibrosis for Longitudinal Assessment of Fibrosis in Chronic Liver Disease: Are They Ready for Prime Time?. The American Journal of Gastroenterology 2006; 101(7): 1497 doi: 10.1111/j.1572-0241.2005.00304.x
|
57 |
Lujie Lin, Mingxiao Zhang, Huijuan Xie, Min Yang, Tong Zhu, Junxuan Yang, Bin Yang, Hua Li. Effects of Schisandrae Fructus alone or in combination in viral hepatitis treatment: A systematic review and meta-analysis of randomized controlled trials. Science of Traditional Chinese Medicine 2024; doi: 10.1097/st9.0000000000000039
|
58 |
Julia Kzhyshkowska, A. Gratchev, S. Goerdt. Stabilin-1, a homeostatic scavenger receptor with multiple functions. Journal of Cellular and Molecular Medicine 2006; 10(3): 635 doi: 10.1111/j.1582-4934.2006.tb00425.x
|
59 |
Mohamed Abo El-Asrar, Nancy Samir Elbarbary, Eman Abdel Rahman Ismail, Ahmed Mohamed Elshenity. Serum YKL-40 in young patients with β-thalassemia major: Relation to hepatitis C virus infection, liver stiffness by transient elastography and cardiovascular complications. Blood Cells, Molecules, and Diseases 2016; 56(1): 1 doi: 10.1016/j.bcmd.2015.09.006
|
60 |
Manuel Romero-Gómez, Emilio Gómez-González, Ana Madrazo, Marina Vera-Valencia, Luis Rodrigo, Ramón Pérez-Alvarez, Rosa Pérez-López, Victor M. Castellano-Megias, Manuel Nevado-Santos, Juan C. Alcón, Ricard Solá, José M. Pérez-Moreno, José M. Navarro, Raúl J. Andrade, Javier Salmerón, Manuel Fernández-López, Rafael Aznar, Moisés Diago. Optical analysis of computed tomography images of the liver predicts fibrosis stage and distribution in chronic hepatitis C. Hepatology 2008; 47(3): 810 doi: 10.1002/hep.22112
|
61 |
Timo Rath, Martin Roderfeld, Can Güler, Christian Wenzel, Jürgen Graf, Frigga Beitinger, Elke Roeb, Reinhart Zachoval. YKL-40 and transient elastography, a powerful team to assess hepatic fibrosis. Scandinavian Journal of Gastroenterology 2011; 46(11): 1369 doi: 10.3109/00365521.2011.613949
|
62 |
Preeti Mehta, Robert Ploutz-Snyder, Jyotirmoy Nandi, Sekou R. Rawlins, Schuyler O. Sanderson, Robert A. Levine. Diagnostic Accuracy of Serum Hyaluronic Acid, FIBROSpect II, and YKL-40 for Discriminating Fibrosis Stages in Chronic Hepatitis C. The American Journal of Gastroenterology 2008; 103(4): 928 doi: 10.1111/j.1572-0241.2007.01761.x
|
63 |
Abdelfattah M. Attallah, El-Shahat A. Toson, Ahmad M. El-Waseef, Mosaad A. Abo-Seif, Mohamed M. Omran, Gamal E. Shiha. Discriminant function based on hyaluronic acid and its degrading enzymes and degradation products for differentiating cirrhotic from non-cirrhotic liver diseased patients in chronic HCV infection. Clinica Chimica Acta 2006; 369(1): 66 doi: 10.1016/j.cca.2006.01.004
|
64 |
Cristina Stasi, Stefano Milani. Non-invasive assessment of liver fibrosis: Between prediction/prevention of outcomes and cost-effectiveness. World Journal of Gastroenterology 2016; 22(4): 1711-1720 doi: 10.3748/wjg.v22.i4.1711
|
65 |
Laurent Castera. Non-invasive assessment of liver fibrosis in chronic hepatitis C. Hepatology International 2011; 5(2): 625 doi: 10.1007/s12072-010-9240-0
|
66 |
|
67 |
Xin-Qiang Xiao, Tarek Hassanein, Li Qun-Fang, Wei Liu, Yu-Huang Zheng, Jun Chen. YKL-40 expression in human hepatocellular carcinoma: a potential biomarker?. Hepatobiliary & Pancreatic Diseases International 2011; 10(6): 605 doi: 10.1016/S1499-3872(11)60103-3
|
68 |
Peter Jarčuška, Martin Janičko, Eduard Veselíny, Pavol Jarčuška, Ľubomír Skladaný. Circulating markers of liver fibrosis progression. Clinica Chimica Acta 2010; 411(15-16): 1009 doi: 10.1016/j.cca.2010.04.009
|
69 |
Hui Tao, Jing-Jing Yang, Kai-Hu Shi, Cheng Huang, Lei Zhang, Xiong-Wen Lv, Jun Li. The significance of YKL-40 protein in liver fibrosis. Inflammation Research 2014; 63(4): 249 doi: 10.1007/s00011-013-0698-9
|
70 |
Maurizio Soresi, Lydia Giannitrapani, Melchiorre Cervello, Anna Licata, Giuseppe Montalto. Non invasive tools for the diagnosis of liver cirrhosis. World Journal of Gastroenterology 2014; 20(48): 18131-18150 doi: 10.3748/wjg.v20.i48.18131
|
71 |
Pamela Valva, Daniela A Ríos, Elena De Matteo, Maria V Preciado. Chronic hepatitis C virus infection: Serum biomarkers in predicting liver damage. World Journal of Gastroenterology 2016; 22(4): 1367-1381 doi: 10.3748/wjg.v22.i4.1367
|
72 |
Sreelakshmi Kotha, ShuetFong Neong, Keyur Patel. Serum biomarkers for diagnosis and monitoring viral hepatitis and hepatocellular carcinoma. Expert Review of Molecular Diagnostics 2018; 18(8): 713 doi: 10.1080/14737159.2018.1496020
|
73 |
David Nunes, Catherine Fleming, Gwynneth Offner, Donald Craven, Oren Fix, Timothy Heeren, Margaret J Koziel, Camilla Graham, Sheila Tumilty, Paul Skolnik, Sherri Stuver, Robert C Horsburgh, Deborah Cotton. Noninvasive Markers of Liver Fibrosis Are Highly Predictive of Liver-Related Death in a Cohort of HCV-Infected Individuals With and Without HIV Infection. American Journal of Gastroenterology 2010; 105(6): 1346 doi: 10.1038/ajg.2009.746
|
74 |
Salvador Resino, José M Bellón, Cristina Asensio, Dariela Micheloud, Pilar Miralles, Ana Vargas, Pilar Catalán, Juan C López, Emilio Álvarez, Jaime Cosin, Raquel Lorente, María A Muñoz-Fernández, Juan Berenguer. Can serum hyaluronic acid replace simple non-invasive indexes to predict liver fibrosis in HIV/Hepatitis C coinfected patients?. BMC Infectious Diseases 2010; 10(1) doi: 10.1186/1471-2334-10-244
|
75 |
Giada Sebastiani, Alfredo Alberti. Non invasive fibrosis biomarkers reduce but not substitute the need for liver biopsy. World Journal of Gastroenterology 2006; 12(23): 3682-3694 doi: 10.3748/wjg.v12.i23.3682
|
76 |
Ummugulsum Can. Biomarkers in Nutrition. Biomarkers in Disease: Methods, Discoveries and Applications 2022; : 767 doi: 10.1007/978-3-031-07389-2_45
|
77 |
Axel M Gressner, Chun-Fang Gao, Olav A Gressner. Non-invasive biomarkers for monitoring the fibrogenic process in liver: A short survey. World Journal of Gastroenterology 2009; 15(20): 2433-2440 doi: 10.3748/wjg.15.2433
|
78 |
O.A. Gressner, R. Weiskirchen, A.M. Gressner. Biomarkers of hepatic fibrosis, fibrogenesis and genetic pre‐disposition pending between fiction and reality. Journal of Cellular and Molecular Medicine 2007; 11(5): 1031 doi: 10.1111/j.1582-4934.2007.00092.x
|
79 |
Tianhui Liu, Xiaoming Wang, Morten A. Karsdal, Diana J. Leeming, Federica Genovese. Molecular Serum Markers of Liver Fibrosis. Biomarker Insights 2012; 7: BMI.S10009 doi: 10.4137/BMI.S10009
|
80 |
Leonardo L. Schiavon, Roberto J. Carvalho-Filho, Janaína L. Narciso-Schiavon, José O. Medina-Pestana, Valéria P. Lanzoni, Maria Lucia G. Ferraz, Antonio Eduardo B. Silva. YKL-40 and hyaluronic acid (HA) as noninvasive markers of liver fibrosis in kidney transplant patients with HCV chronic infection. Scandinavian Journal of Gastroenterology 2010; 45(5): 615 doi: 10.3109/00365521003637203
|
81 |
J. O. SMITH, R. K. STERLING. Systematic review: non‐invasive methods of fibrosis analysis in chronic hepatitis C. Alimentary Pharmacology & Therapeutics 2009; 30(6): 557 doi: 10.1111/j.1365-2036.2009.04062.x
|
82 |
Hamed Khalili, Barham Abu Dayyeh, Lawrence S. Friedman. Chronic Liver Failure. 2011; : 47 doi: 10.1007/978-1-60761-866-9_3
|
83 |
David S. Kotlyar, Wojciech Blonski, Vinod K. Rustgi. Noninvasive Monitoring of Hepatitis C Fibrosis Progression. Clinics in Liver Disease 2008; 12(3): 557 doi: 10.1016/j.cld.2008.03.006
|
84 |
Salvatore Musumeci. Biomarkers in Liver Disease. Biomarkers in Disease: Methods, Discoveries and Applications 2017; : 513 doi: 10.1007/978-94-007-7675-3_21
|
85 |
Olav A. Gressner, Chunfang Gao. Monitoring fibrogenic progression in the liver. Clinica Chimica Acta 2014; 433: 111 doi: 10.1016/j.cca.2014.02.021
|
86 |
Laurent Castera. Assessing liver fibrosis. Expert Review of Gastroenterology & Hepatology 2008; 2(4): 541 doi: 10.1586/17474124.2.4.541
|
87 |
Ummugulsum Can. Biomarkers in Nutrition. Biomarkers in Disease: Methods, Discoveries and Applications 2022; : 1 doi: 10.1007/978-3-030-81304-8_45-1
|
88 |
Giada Sebastiani, Konstantinos Gkouvatsos, Mario Plebani. Non-invasive assessment of liver fibrosis: it is time for laboratory medicine. cclm 2011; 49(1): 13 doi: 10.1515/CCLM.2011.001
|
89 |
Frederick D. Coffman. Chitinase 3-Like-1 (CHI3L1): A Putative Disease Marker at the Interface of Proteomics and Glycomics. Critical Reviews in Clinical Laboratory Sciences 2008; 45(6): 531 doi: 10.1080/10408360802334743
|
90 |
Shuwei Wang, Mengyuan Hu, Yunsong Qian, Zhenluo Jiang, Lili Shen, Liyun Fu, Yaoren Hu. CHI3L1 in the pathophysiology and diagnosis of liver diseases. Biomedicine & Pharmacotherapy 2020; 131: 110680 doi: 10.1016/j.biopha.2020.110680
|
91 |
Marija Zeremski, Andrew H. Talal. Noninvasive markers of hepatic fibrosis: Are they ready for prime time in the management of HIV/HCV co-infected patients?. Journal of Hepatology 2005; 43(1): 2 doi: 10.1016/j.jhep.2005.05.007
|
92 |
Hatem A. El-mezayen, El-Shahat A. Toson, Gamal E. Shiha. Role of hyaluronic acid, its degrading enzymes, degradation products, and ferritin in the assessment of fibrosis stage in Egyptian patients with chronic hepatitis C. European Journal of Gastroenterology & Hepatology 2013; 25(1): 69 doi: 10.1097/MEG.0b013e3283594924
|
93 |
Toshikazu Araoka, Hiroya Takeoka, Keisuke Nishioka, Seiji Kishi, Makoto Araki, Fumi Kishi, Reiko Shigeta, Taichi Murakami, Naoki Kondo, Motokazu Matsuura, Kazuhiro Yoshikawa, Akira Mima, Kojiro Nagai, Toshikazu Takahashi, Hideharu Abe, Masaki Ikeda, Makiko Kondo, Azusa Sugiyama, Masahiko Sugano, Toshio Doi. Safety and efficacy of interferon-beta therapy for hemodialysis patient with HCV. Nihon Toseki Igakkai Zasshi 2009; 42(5): 393 doi: 10.4009/jsdt.42.393
|
94 |
Masahiro Tamura, Hiroshi Ohta, Genya Shimbo, Tatsuyuki Osuga, Noboru Sasaki, Keitaro Morishita, Yumiko Kagawa, Mitsuyoshi Takiguchi. Usefulness of noninvasive shear wave elastography for the assessment of hepatic fibrosis in dogs with hepatic disease. Journal of Veterinary Internal Medicine 2019; 33(5): 2067 doi: 10.1111/jvim.15598
|
95 |
G. Sebastiani, A. Alberti. How far is noninvasive assessment of liver fibrosis from replacing liver biopsy in hepatitis C?. Journal of Viral Hepatitis 2012; 19(s1): 18 doi: 10.1111/j.1365-2893.2011.01518.x
|
96 |
Bengu Tatar, Sukran Kose, Emel Pala, Erhan Tatar. Inflammatory Biomarkers and Liver Histopathology in Non-Uremic and Uremic Chronic Hepatitis C Patients. Acta Medica (Hradec Kralove, Czech Republic) 2017; 60(2): 71 doi: 10.14712/18059694.2017.96
|
97 |
Salvatore Musumeci. Biomarkers in Liver Disease. Biomarkers in Disease: Methods, Discoveries and Applications 2016; : 1 doi: 10.1007/978-94-007-7742-2_21-1
|
98 |
Tuija Väänänen, Lauri Lehtimäki, Katriina Vuolteenaho, Mari Hämäläinen, Panu Oksa, Tuula Vierikko, Ritva Järvenpää, Jukka Uitti, Hannu Kankaanranta, Eeva Moilanen. Glycoprotein YKL-40 Levels in Plasma Are Associated with Fibrotic Changes on HRCT in Asbestos-Exposed Subjects. Mediators of Inflammation 2017; 2017: 1 doi: 10.1155/2017/1797512
|
99 |
Caterina Sagnelli, Salvatore Martini, Mariantonietta Pisaturo, Giuseppe Pasquale, Margherita Macera, Rosa Zampino, Nicola Coppola, Evangelista Sagnelli. Liver fibrosis in human immunodeficiency virus/hepatitis C virus coinfection: Diagnostic methods and clinical impact. World Journal of Hepatology 2015; 7(24): 2510-2521 doi: 10.4254/wjh.v7.i24.2510
|
100 |
O.A. Gressner, A.M. Gressner. Liver Pathophysiology. 2017; : 547 doi: 10.1016/B978-0-12-804274-8.00041-2
|
101 |
Julia Maroto-García, Ana Moreno Álvarez, María P. Sanz de Pedro, Antonio Buño-Soto, Álvaro González. Serum biomarkers for liver fibrosis assessment. Advances in Laboratory Medicine / Avances en Medicina de Laboratorio 2024; 5(2): 115 doi: 10.1515/almed-2023-0081
|
102 |
Jacob Alexander, Bruce Y. Tung, Anne Croghan, Kris V. Kowdley. Effect of iron depletion on serum markers of fibrogenesis, oxidative stress and serum liver enzymes in chronic hepatitis C: results of a pilot study. Liver International 2007; 27(2): 268 doi: 10.1111/j.1478-3231.2007.01449.x
|
103 |
Ju Dong Yang, Eugene Kim, Rachel A. Pedersen, W. Ray Kim, Surakit Pungpapong, Lewis R. Roberts. Utility of Serum YKL-40 as a Tumor-Specific Marker of Hepatobiliary Malignancies. Gut and Liver 2010; 4(4): 537 doi: 10.5009/gnl.2010.4.4.537
|
104 |
Suraj Sharma, Korosh Khalili, Geoffrey Christopher Nguyen. Non-invasive diagnosis of advanced fibrosis and cirrhosis. World Journal of Gastroenterology 2014; 20(45): 16820-16830 doi: 10.3748/wjg.v20.i45.16820
|
105 |
Yasser E Nassef, Mones M Abu Shady, Essam M Galal, Manal A Hamed. Performance of diagnostic biomarkers in predicting liver fibrosis among hepatitis C virus-infected Egyptian children. Memórias do Instituto Oswaldo Cruz 2013; 108(7): 887 doi: 10.1590/0074-0276130139
|
106 |
Shelley S Selph, Alexander D Ginsburg, Roger Chou. Impact of contacting study authors to obtain additional data for systematic reviews: diagnostic accuracy studies for hepatic fibrosis. Systematic Reviews 2014; 3(1) doi: 10.1186/2046-4053-3-107
|
107 |
Ulrike W. Denzer, Stefan Lüth. Non-invasive diagnosis and monitoring of liver fibrosis and cirrhosis. Best Practice & Research Clinical Gastroenterology 2009; 23(3): 453 doi: 10.1016/j.bpg.2009.03.002
|
108 |
Catriona Crossan, Emmanuel A Tsochatzis, Louise Longworth, Kurinchi Gurusamy, Brian Davidson, Manuel Rodríguez-Perálvarez, Konstantinos Mantzoukis, Julia O’Brien, Evangelos Thalassinos, Vassilios Papastergiou, Andrew Burroughs. Cost-effectiveness of non-invasive methods for assessment and monitoring of liver fibrosis and cirrhosis in patients with chronic liver disease: systematic review and economic evaluation. Health Technology Assessment 2015; 19(9): 1 doi: 10.3310/hta19090
|
109 |
David U. Olveda, Remigio M. Olveda, Donald P. McManus, Pengfei Cai, Thao N.P. Chau, Alfred K. Lam, Yuesheng Li, Donald A. Harn, Marilyn L. Vinluan, Allen G.P. Ross. The chronic enteropathogenic disease schistosomiasis. International Journal of Infectious Diseases 2014; 28: 193 doi: 10.1016/j.ijid.2014.07.009
|
110 |
Mansi Prakash, Manish Bodas, Divya Prakash, Neelu Nawani, Madhukar Khetmalas, Abul Mandal, Cecilia Eriksson. Diverse pathological implications of YKL-40: Answers may lie in ‘outside-in’ signaling. Cellular Signalling 2013; 25(7): 1567 doi: 10.1016/j.cellsig.2013.03.016
|
111 |
Yoav Lurie, Muriel Webb, Ruth Cytter-Kuint, Shimon Shteingart, Gerardo Z Lederkremer. Non-invasive diagnosis of liver fibrosis and cirrhosis. World Journal of Gastroenterology 2015; 21(41): 11567-11583 doi: 10.3748/wjg.v21.i41.11567
|
112 |
Mette J. Nielsen, Konstantin Kazankov, Diana J. Leeming, Morten A. Karsdal, Aleksander Krag, Francisco Barrera, Duncan McLeod, Jacob George, Henning Grønbæk, Matias A Avila. Markers of Collagen Remodeling Detect Clinically Significant Fibrosis in Chronic Hepatitis C Patients. PLOS ONE 2015; 10(9): e0137302 doi: 10.1371/journal.pone.0137302
|